| Q60907434 | A Specific Circulating MicroRNA Cluster Is Associated to Late Differential Cardiac Response to Doxorubicin-Induced Cardiotoxicity |
| Q33658456 | Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care |
| Q97439633 | Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment |
| Q37701713 | Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients |
| Q48178650 | Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients |
| Q36409311 | Comment on "MicroRNA-208a Silencing Attenuates Doxorubicin Induced Myocyte Apoptosis and Cardiac Dysfunction" |
| Q47777069 | Comprehensive Analysis of Circulating microRNA Specific to the Liver, Heart, and Skeletal Muscle of Cynomolgus Monkeys. |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q89457522 | Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications |
| Q38616581 | Development and regulatory application of microRNA biomarkers |
| Q36912561 | Doxorubicin induced heart failure: Phenotype and molecular mechanisms. |
| Q36025057 | Editor's Highlight: Plasma miR-183/96/182 Cluster and miR-124 are Promising Biomarkers of Rat Retinal Toxicity |
| Q64262548 | Effects of microRNA-208a on inflammation and oxidative stress in ketamine-induced cardiotoxicity through Notch/NF-κB signal pathways by CHD9 |
| Q52868874 | Glomerulonephritis-Induced Changes in Urinary and Kidney MicroRNA Profiles in Rats. |
| Q91456454 | Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Soluble Factors from Human Mesenchymal Stem Cells |
| Q37412904 | MicroRNA profiles in a monkey testicular injury model induced by testicular hyperthermia |
| Q37641769 | MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat. |
| Q45352157 | MicroRNAs and toxicology: A love marriage |
| Q90461158 | MicroRNAs in Cancer Treatment-Induced Cardiotoxicity |
| Q39304689 | MicroRNAs in injury and repair |
| Q97643665 | Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets |
| Q31004210 | Paving the Route to Plasma miR-208a-3p as an Acute Cardiac Injury Biomarker: Preclinical Rat Data Supports Its Use in Drug Safety Assessment |
| Q92881879 | Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection |
| Q38944060 | Recent progress toward the use of circulating microRNAs as clinical biomarkers |
| Q91876482 | Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis |
| Q47929107 | Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients. |
| Q47676301 | Sertoli Cells Loaded with Doxorubicin in Lipid Micelles Reduced Tumor Burden and Dox-Induced Toxicity |
| Q45967235 | Technological Advances in Cardiovascular Safety Assessment Decrease Preclinical Animal Use and Improve Clinical Relevance. |
| Q38367620 | The role for microRNAs in drug toxicity and in safety assessment |
| Q26778915 | Translating extracellular microRNA into clinical biomarkers for drug-induced toxicity: from high-throughput profiling to validation |
| Q49163835 | Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients |
| Q90448502 | miR-140-5p mediates bevacizumab-induced cytotoxicity to cardiomyocytes by targeting the VEGFA/14-3-3γ signal pathway |
| Q26778918 | microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment |
| Q89539732 | microRNAs: Potential biomarkers of toxicity: A special issue of the journal Toxicology Reports |